SEC Proposes Expanded Offering Reforms for Closed-End Funds and BDCs

IRS Announces Intent to Issue Regulations on Expanded Executive Compensation Excise Tax for Tax-Exempt Organizations

This episode breaks down how the One Big Beautiful Bill Act (OBBA) expands the Section 4960 excise tax on executive compensation, shifting the definition of "covered employee" from the top five earners to any employee earning over $1 million. The discussion covers key changes, including preserved and eliminated exceptions for related organization employees, and clarifies the retroactive reach of the new rules.

New York's Expanded Health Care Transaction Oversight Bill Fails for the Second Consecutive Year

This episode provides a concise update on New York’s health care transaction oversight following the 2026–2027 state budget. Hosts discuss the exclusion of proposed amendments, how New York’s requirements compare to other states, and what health care entities and investors should watch for next.

SEC Proposes Expanded Offering Reforms for Closed-End Funds and BDCs

In this episode, we deliver a concise analysis of the SEC’s May 19, 2026 release proposing major amendments to the registered offering framework for business development companies (BDCs) and registered closed-end funds (CEFs). The discussion centers on the SEC’s push for parity between these funds and operating companies, including the elimination of public float thresholds, the introduction of new eligibility categories based on exchange listing and reporting compliance, and expanded access to short-form registration and shelf offerings. We also break down the implications for unlisted and non-traded funds, including federal preemption of state registration for certain BDCs and changes to Rule 473.

SEC Proposes Major Overhaul of Public Company Reporting Framework: Two-Tier Filer Status System, Expanded Disclosure Accommodations, and New Relief for the Smallest Filers

In this episode, we break down the SEC’s May 19, 2026 proposed amendments to the public company reporting framework. The discussion covers the most sweeping simplification of filer status in over twenty years, including the elimination of intermediate filer categories and a sharp increase in the large accelerated filer (LAF) threshold from $700 million to $2 billion. We explain how these changes will shift nearly 80% of public companies to non-accelerated filer (NAF) status, resulting in significant compliance cost reductions and streamlined reporting requirements.

China’s NMPA Issues Final Measures on Regulatory Data Protection

This episode offers a concise breakdown of China’s National Medical Products Administration (NMPA) and its newly issued implementation measures for drug trial data protection, effective May 15, 2026. The hosts explain which types of data are eligible for protection, detail the NMPA’s tiered system—ranging from six years for innovative drugs to zero for follow-on generics—and clarify the procedural requirements for securing these rights. They also discuss the critical operational impacts for life sciences companies, including the need for early strategic planning and the implications of strict filing windows.